GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs, Inc. (NASDAQ:GOVX) saw a large increase in short interest in February. As of February 15th, there was short interest totalling 762,600 shares, an increase of 35.5% from the January 31st total of 563,000 shares. Based on an average daily volume of 642,400 shares, the short-interest ratio is currently 1.2 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Alliance Global Partners began coverage on shares of GeoVax Labs in a report on Monday, November 11th. They set a “buy” rating and a $15.00 price target for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a research note on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a research note on Friday, November 15th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $14.20.

GeoVax Labs Stock Up 4.9 %

Shares of GOVX stock opened at $1.51 on Tuesday. GeoVax Labs has a one year low of $1.09 and a one year high of $11.18. The company has a 50 day moving average price of $1.98 and a 200 day moving average price of $2.63.

Institutional Trading of GeoVax Labs

A number of institutional investors and hedge funds have recently made changes to their positions in GOVX. Northern Trust Corp purchased a new stake in GeoVax Labs during the fourth quarter valued at about $29,000. Virtu Financial LLC acquired a new position in shares of GeoVax Labs in the 3rd quarter valued at about $97,000. Citadel Advisors LLC purchased a new stake in shares of GeoVax Labs during the 4th quarter worth about $104,000. Finally, Geode Capital Management LLC increased its position in GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after purchasing an additional 33,440 shares in the last quarter. 6.09% of the stock is currently owned by institutional investors and hedge funds.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.